 1. Patients who are known to have somatic tumor mutations in the following genes, for which targeted agents are available that directly affect the treatment of brain metastasis: Anaplastic lymphoma kinase ALK, epidermal growth factor receptor EGFR, ROS-1 proto-oncogene, and proto-oncogene B-RAF 